Abcam, ab4717, Anti-ABL1 (phospho Y412) antibody

Size: 50µL
Rabbit Polyclonal ABL1 phospho Y412 antibody. Suitable for WB and reacts with Human samples. Cited in 9 publications. Immunogen corresponding to Synthetic Peptide within Human ABL1 phospho Y412.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Synthetic Peptide within Human ABL1 phospho Y412. The exact immunogen used to generate this antibody is proprietary information.P00519

Product details:
c-Abl is a 140-150 kDa non-receptor protein tyrosine kinase whose precise functions are not known, but roles for Abl in growth factor and integrin signaling, cell cycle regulation, cytoskeletal reorganization, neurogenesis, and responses to DNA damage and oxidative stress have been suggested. c-Abl kinase activity is increased in vivo by diverse physiological stimuli including ionizing radiation, entry into S phase, integrin activation, and platelet-derived growth factor (PDGF) stimulation. c-Abl contains various protein binding domains that appear to enable it to regulate the functions of many proteins by forming complexes, most notably three isoforms of the oncogenic protein Bcr/Abl. c-Abl becomes fully activated by sequential phosphorylation of tyrosines 412 and 245.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Purification notes-Purified from rabbit serum by sequential epitope-specific chromatography. The antibody has been negatively pre-adsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated c-Abl. The final product is generated by affinity chromatography using a c-Abl derived peptide that is phosphorylated at tyrosine 245., Storage buffer-pH: 7.3Preservative: 0.05% Sodium azideConstituents: PBS, 0.1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
ABL1 also referred to as ABL-1 or ABL1 protein is a non-receptor tyrosine kinase with a mass of approximately 120 kDa. It is found throughout the body in diverse tissues with significant expression in the brain testes and hematopoietic cells. This protein consists of several functional domains including SH3 SH2 and a kinase domain that facilitate its interaction with various cellular components. ABL1 kinase plays a central role in cell differentiation division and stress response reflecting its mechanical versatility in cellular signaling.
Biological function summary
ABL1 functions by regulating key processes like cell cycle progression actin dynamics and cell adhesion. ABL1 participates as part of larger protein complexes that modulate cellular movement and gene transcription. When activated it phosphorylates a range of substrates that leads to various cellular outcomes. ABL1 operates in the cytoplasm and nucleus influencing both cytoskeletal rearrangement and DNA repair which highlights its critical function in maintaining cellular integrity and response to damage.
Pathways
ABL1 interacts in both the mitogenic and apoptotic pathways including involvement in the MAPK and PI3K/AKT pathways. ABL1 interfaces with proteins like CRK and GRB2 in these pathways integrating signals that determine cell fate decisions. Through its kinase activity ABL1 mediates signaling cascades that impact cellular growth and survival responding dynamically to internal and external cues.
ABL1 is notoriously implicated in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). The fusion protein BCR-ABL1 resulting from chromosomal translocation drives oncogenic signals that promote uncontrolled cell proliferation. The aberrant activity of BCR-ABL1 disrupts normal cellular regulation and interacts with proteins such as STAT5 enhancing leukemogenesis. Targeted therapies like tyrosine kinase inhibitors specifically hinder BCR-ABL1 activity demonstrating ABL1's importance in cancer pathology and treatment.